These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Pharmacokinetic and pharmacodynamic studies on recombinant human erythropoietin.
    Author: Salmonson T.
    Journal: Scand J Urol Nephrol Suppl; 1990; 129():1-66. PubMed ID: 2255869.
    Abstract:
    In order to optimize the treatment of anemia in uremic patients the pharmacokinetic and pharmacodynamic properties of recombinant erythropoietin (r-Epo) were studied after i.v., s.c. and i.p. administration. Both in healthy volunteers and in patient with chronic renal failure, the half-life of r-Epo after i.v. administration was short (about 6 h) in comparison with the commonly used dosing interval of 3 to 7 days. Hence, the minimum serum concentration during a dosing interval is expected to be less than 1% of the peak concentration. Absorption following a s.c. dose was slow, resulting in a markedly different concentration-time profile in comparison to i.v. dosing. The half-life was about 25 h and only approximately 25% of the given dose reached the systemic circulation. As a result of differences in concentration-time profiles, higher trough concentrations during s.c. dosing intervals may be expected in comparison to those occurring after i.v. dosing. When r-Epo was given i.p. (diluted in dialysate) the extent of systemic absorption depended on the dwell time in the peritoneal cavity. A long administration time was required to absorb an amount of r-Epo predicted from s.c. studies to be adequate to achieve the desired clinical effect. In spite of reduced bioavailability, s.c. treatment did not require higher r-Epo doses than i.v. treatment to maintain the desired hemoglobin concentration. On the contrary, a trend to a requirement for lower doses was detected. The pharmacodynamic and pharmacokinetic results strongly indicate a more efficacious concentration-time profile following s.c. administration. Since s.c. dosing also allows self-administration the use of this administration route is recommended. To simplify the treatment of anemic patients with r-Epo, a model was developed to predict the required weekly s.c. dose. To facilitate the use of this model a nomogram was constructed.
    [Abstract] [Full Text] [Related] [New Search]